Bullish indicating open at $55-$60, IPO prices at $37
Dimitar Slavchev, CEO, CFO, and President of Nika Pharmaceuticals, Inc. (NASDAQ:NIKA), has sold 2 million shares of the company’s common stock, according to a recent SEC filing. The sale comes amid a significant 220% surge in the company’s stock price over the past six months, though InvestingPro analysis indicates the stock is currently overvalued. The transaction, which took place on March 18, 2025, was executed at a price of $0.25 per share, amounting to a total value of $500,000. Following the sale, Slavchev retains ownership of 455,589,500 shares. The transaction was reported in a Form 4 filing with the Securities and Exchange Commission. InvestingPro data reveals concerning fundamentals, including negative free cash flow and a weak financial health score. Subscribers can access additional insights and 12+ more ProTips about NIKA’s financial position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.